Stocks · News reference

ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.

Aug 7, 2026, 6:26 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 24, 2026, 11:01 AMSEC EDGAR
8-K filing — ANI PHARMACEUTICALS INC (ANIP)
Filed: 2026-08-24 AccNo: 0001023024-26-000071 Size: 173 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgar
ANIP
BenzingaAug 10, 2026, 2:39 PMAvi Kapoor
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.
Read original at benzinga
ANIP
BenzingaAug 10, 2026, 2:07 PMBenzinga Newsdesk
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.
Read original at benzinga
ANIP
BenzingaAug 10, 2026, 12:27 PMBenzinga Newsdesk
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.
Read original at benzinga
ANIP